{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:57:07Z","timestamp":1792205827560,"version":"4.4.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Fibroblast growth factor 21 (FGF21) has emerged as a key metabolic hormone with cardioprotective roles in heart failure (HF). It is produced by the liver, adipose tissue, and cardiomyocytes and acts through fibroblast growth factor receptor 1\/\u03b2-Klotho to regulate glucose uptake, fatty acid oxidation, mitochondrial function, and adaptive stress responses. Experimental models show that FGF21 protects against pressure overload, ischemia\u2013reperfusion injury, doxorubicin cardiotoxicity, and diabetic cardiomyopathy by enhancing oxidative metabolism and autophagy, suppressing inflammation, boosting antioxidant defenses, and reducing fibrosis. In humans, circulating FGF21 levels are elevated across HF phenotypes and correlate with N-terminal pro\u2013B-type natriuretic peptide, inflammatory cytokines, adverse remodeling, and poor prognosis, suggesting compensatory upregulation in the context of \u201cFGF21 resistance.\u201d Long-acting FGF21 analogs developed for metabolic diseases, such as pegozafermin and efruxifermin, improve triglycerides, insulin sensitivity, and ectopic fat, highlighting potential cardiovascular benefit. Despite these advances, several uncertainties remain. It is unclear whether FGF21 primarily reflects a biomarker of stress or actively modifies disease progression in humans. The relative importance of direct cardiac signaling versus systemic pathways remains unresolved, as does the role of receptor isoform specificity, particularly FGFR4-mediated hypertrophy seen in diabetic settings. Reference ranges and standardized assays are lacking, and long-term safety concerns such as bone loss or cachexia need further study. This review integrates molecular, preclinical, and clinical evidence to position FGF21 as both a marker and a therapeutic target in HF. It aims to focus on mechanisms of action, evaluate its prognostic value, assess therapeutic analogs, and outline future directions for translating FGF21 into metabolism-focused strategies for HF management.<\/jats:p>","DOI":"10.1097\/crd.0000000000001102","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:02:28Z","timestamp":1762480948000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Role of FGF21 in Heart Failure: Molecular Insights and Therapeutic Implications"],"prefix":"10.1097","author":[{"given":"Siddharth Pravin","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Tannous","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu C.","family":"Tated","sequence":"additional","affiliation":[{"name":"Department of Public Health, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshil Kumar","family":"Maheta","sequence":"additional","affiliation":[{"name":"Department of Public Health, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishkar","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texila American University, Georgetown, Guyana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hritvik","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishma","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"R1-20251118","doi-asserted-by":"crossref","first-page":"n461","DOI":"10.1136\/bmj.n461","article-title":"Age dependent associations of risk factors with heart failure: pooled population based cohort study.","volume":"372","author":"Tromp","year":"2021","journal-title":"BMJ"},{"key":"R2-20251118","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1053\/euhj.2000.2533","article-title":"The prognosis of heart failure in the general population: the Rotterdam Study.","volume":"22","author":"Mosterd","year":"2001","journal-title":"Eur Heart J"},{"key":"R3-20251118","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual global economic burden of heart failure.","volume":"171","author":"Cook","year":"2014","journal-title":"Int J Cardiol"},{"key":"R4-20251118","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding.","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"R5-20251118","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21.","volume":"78","author":"Fisher","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"R6-20251118","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41467-025-56885-9","article-title":"FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice.","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"R7-20251118","doi-asserted-by":"crossref","first-page":"e008910","DOI":"10.1161\/CIRCHEARTFAILURE.121.008910","article-title":"FGF21 (Fibroblast Growth Factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure.","volume":"15","author":"Sommakia","year":"2021","journal-title":"Circ Heart Fail"},{"key":"R8-20251118","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/ncomms3019","article-title":"Fibroblast growth factor 21 protects against cardiac hypertrophy in mice.","volume":"4","author":"Planavila","year":"2013","journal-title":"Nat Commun"},{"key":"R9-20251118","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ehf2.12502","article-title":"Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation.","volume":"6","author":"Refsgaard Holm","year":"2019","journal-title":"ESC Heart Fail"},{"key":"R10-20251118","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"R11-20251118","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1097\/CM9.0000000000001890","article-title":"The role of FGF21 in the pathogenesis of cardiovascular disease.","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"R12-20251118","doi-asserted-by":"crossref","first-page":"1202730","DOI":"10.3389\/fcvm.2023.1202730","article-title":"Mechanism of fibroblast growth factor 21 in cardiac remodeling.","volume":"10","author":"Zhao","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R13-20251118","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10753-017-0665-7","article-title":"FGF-21 plays a crucial role in the glucose uptake of activated monocytes.","volume":"41","author":"Wang","year":"2017","journal-title":"Inflammation"},{"key":"R14-20251118","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbrc.2015.02.081","article-title":"FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism.","volume":"459","author":"Joki","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"R15-20251118","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00395-019-0768-4","article-title":"Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR-143\/EGR1 axis.","volume":"115","author":"Li","year":"2020","journal-title":"Basic Res Cardiol"},{"key":"R16-20251118","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.1038\/s41598-022-11033-x","article-title":"FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes.","volume":"12","author":"Yanucil","year":"2022","journal-title":"Sci Rep"},{"key":"R17-20251118","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1152\/japplphysiol.00307.2023","article-title":"FGF21 promotes myocardial angiogenesis and mediates the cardioprotective effects of exercise in myocardial infarction mice.","volume":"135","author":"Bo","year":"2023","journal-title":"J Appl Physiol (Bethesda, Md. : 1985)"},{"key":"R18-20251118","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10741-022-10268-0","article-title":"Fibroblast growth factor 21 in heart failure.","volume":"28","author":"Tucker","year":"2022","journal-title":"Heart Fail Rev"},{"key":"R19-20251118","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00125-015-3630-8","article-title":"Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1\/2-dependent signalling pathway.","volume":"58","author":"Zhang","year":"2015","journal-title":"Diabetologia"},{"key":"R20-20251118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12974-020-01921-2","article-title":"FGF21 alleviates neuroinflammation following ischemic stroke by modulating the temporal and spatial dynamics of microglia\/macrophages.","volume":"17","author":"Wang","year":"2020","journal-title":"J Neuroinflammation"},{"key":"R21-20251118","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1139\/cjpp-2021-0454","article-title":"Fibroblast growth factor 21 improves lipopolysaccharide-induced pulmonary microvascular endothelial cell dysfunction and inflammatory response through SIRT1-mediated NF-\u03baB deacetylation.","volume":"100","author":"Zhou","year":"2022","journal-title":"Can J Physiol Pharmacol"},{"key":"R22-20251118","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10753-015-0251-9","article-title":"Treatment of CIA mice with FGF21 down-regulates TH17-IL-17 axis.","volume":"39","author":"Li","year":"2015","journal-title":"Inflammation"},{"key":"R23-20251118","doi-asserted-by":"crossref","first-page":"e3018","DOI":"10.1038\/cddis.2017.410","article-title":"Cardioprotective effects of fibroblast growth factor 21 against doxorubicin-induced toxicity via the SIRT1\/LKB1\/AMPK pathway.","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis"},{"key":"R24-20251118","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/path.5226","article-title":"Fibroblast growth factor\u201021 protects against fibrosis in hypertensive heart disease.","volume":"248","author":"Ferrer\u2010Curriu","year":"2019","journal-title":"J Pathol"},{"key":"R25-20251118","doi-asserted-by":"crossref","first-page":"12341","DOI":"10.3390\/ijms222212341","article-title":"Exercise training alleviates cardiac fibrosis through increasing fibroblast growth factor 21 and regulating TGF-\u03b21-Smad2\/3-MMP2\/9 signaling in mice with myocardial infarction.","volume":"22","author":"Ma","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R26-20251118","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41419-018-0307-5","article-title":"Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart.","volume":"9","author":"Yang","year":"2018","journal-title":"Cell Death Dis"},{"key":"R27-20251118","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/CS20150623","article-title":"Fenofibrate increases cardiac autophagy via FGF21\/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice.","volume":"130","author":"Zhang","year":"2016","journal-title":"Clin Sci (London, England : 1979)"},{"key":"R28-20251118","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cmet.2018.06.013","article-title":"A2A receptor activation attenuates hypertensive cardiac remodeling via promoting brown adipose tissue-derived FGF21.","volume":"28","author":"Ruan","year":"2018","journal-title":"Cell Metab"},{"key":"R29-20251118","doi-asserted-by":"crossref","first-page":"eade4110","DOI":"10.1126\/sciadv.ade4110","article-title":"An IL-6\/STAT3\/MR\/FGF21 axis mediates heart-liver cross-talk after myocardial infarction.","volume":"9","author":"Sun","year":"2023","journal-title":"Sci Adv"},{"key":"R30-20251118","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3390\/diagnostics11091577","article-title":"Diagnostic performance of serum biomarkers fibroblast growth factor 21, galectin-3 and copeptin for heart failure with preserved ejection fraction in a sample of patients with type 2 diabetes mellitus.","volume":"11","author":"Iano\u0219","year":"2021","journal-title":"Diagnostics"},{"key":"R31-20251118","doi-asserted-by":"crossref","first-page":"33953","DOI":"10.1038\/srep33953","article-title":"Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction.","volume":"6","author":"Chou","year":"2016","journal-title":"Sci Rep"},{"key":"R32-20251118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000509239","article-title":"Fibroblast growth factor 21 correlates with the prognosis of dilated cardiomyopathy.","volume":"146","author":"Gu","year":"2020","journal-title":"Cardiology"},{"key":"R33-20251118","doi-asserted-by":"crossref","first-page":"e12235","DOI":"10.7717\/peerj.12235","article-title":"Elevated serum FGF21 predicts the major adverse cardiovascular events in STEMI patients after emergency percutaneous coronary intervention.","volume":"9","author":"Gu","year":"2021","journal-title":"PeerJ"},{"key":"R34-20251118","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects.","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"key":"R35-20251118","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH.","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"R36-20251118","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"R37-20251118","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"R38-20251118","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once\u2010weekly administration of a long\u2010acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non\u2010human primates.","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R39-20251118","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors.","volume":"13","author":"Packer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"R40-20251118","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bcp.13760","article-title":"The influence of heart failure on the pharmacokinetics of cardiovascular and non\u2010cardiovascular drugs: a critical appraisal of the evidence.","volume":"85","author":"Mangoni","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R41-20251118","doi-asserted-by":"crossref","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms.","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"R42-20251118","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bbrc.2007.06.068","article-title":"PPAR\u03b1 is a key regulator of hepatic FGF21.","volume":"360","author":"Lund\u00e5sen","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R43-20251118","doi-asserted-by":"crossref","first-page":"101718","DOI":"10.1016\/j.molmet.2023.101718","article-title":"Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.","volume":"72","author":"Le","year":"2023","journal-title":"Mol Metab"},{"key":"R44-20251118","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ijo.2017.138","article-title":"Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?","volume":"41","author":"Crujeiras","year":"2017","journal-title":"Int J Obes (Lond)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:00:27Z","timestamp":1763427627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":44,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001102","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}